Document Detail


The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles.
MedLine Citation:
PMID:  22074663     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nanomaterials have been increasingly employed as drug(s)-incorporated vectors for drug delivery due to their potential of maximizing therapeutic efficacy while minimizing systemic side effects. However, there have been two main challenges for these vectors: (i) the existing synthetic approaches are cumbersome and incapable of achieving precise control of their structural properties, which will affect their biodistribution and therapeutic efficacies, and (ii) lack of an early checkpoint to quickly predict which drug(s)-incorporated vectors exhibit optimal therapeutic outcomes. In this work, we utilized a new rational developmental approach to rapidly screen nanoparticle (NP)-based cancer therapeutic agents containing a built-in companion diagnostic utility for optimal therapeutic efficacy. The approach leverages the advantages of a self-assembly synthetic method for preparation of two different sizes of drug-incorporated supramolecular nanoparticles (SNPs), and a positron emission tomography (PET) imaging-based biodistribution study to quickly evaluate the accumulation of SNPs at a tumor site in vivo and select the favorable SNPs for in vivo therapeutic study. Finally, the enhanced in vivo anti-tumor efficacy of the selected SNPs was validated by tumor reduction/inhibition studies. We foresee our rational developmental approach providing a general strategy in the search of optimal therapeutic agents among the diversity of NP-based therapeutic agents.
Authors:
Kuan-Ju Chen; Li Tang; Mitch André Garcia; Hao Wang; Hua Lu; Wei-Yu Lin; Shuang Hou; Qian Yin; Clifton K-F Shen; Jianjun Cheng; Hsian-Rong Tseng
Related Documents :
21603223 - Enolase: a key player in the metabolism and a probable virulence factor of trypanosomat...
21632983 - Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
7258873 - Orphan drugs: creating a policy.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-11-08
Journal Detail:
Title:  Biomaterials     Volume:  33     ISSN:  1878-5905     ISO Abbreviation:  Biomaterials     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2011-11-21     Completed Date:  2012-03-07     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  8100316     Medline TA:  Biomaterials     Country:  England    
Other Details:
Languages:  eng     Pagination:  1162-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents, Phytogenic / administration & dosage*,  pharmacokinetics*,  therapeutic use
Camptothecin / administration & dosage*,  pharmacokinetics*,  therapeutic use
Cell Line, Tumor
Drug Carriers / chemistry*
Female
Humans
Mice
Mice, Inbred C57BL
Nanoparticles / chemistry*,  ultrastructure
Neoplasms / drug therapy,  pathology
Positron-Emission Tomography
Tissue Distribution
Grant Support
ID/Acronym/Agency:
1R21CA152627/CA/NCI NIH HHS; R21 1R21EB008419/EB/NIBIB NIH HHS; R21 EB008419/EB/NIBIB NIH HHS; R21 EB008419-02/EB/NIBIB NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Drug Carriers; XT3Z54Z28A/Camptothecin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aort...
Next Document:  Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted de...